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Background: This study describes the characteristics of a large sample of patients hospitalised
for the first time for a chronic obstructive pulmonary disease (COPD) exacerbation.
Methods: All subjects first admitted for a COPD exacerbation to nine teaching Spanish hospitals
during January 2004eMarch 2006, were eligible. COPD diagnosis was confirmed by spirometry
under stability. At admission, sociodemographic data, lifestyle, previous treatment and diag-
nosis of respiratory disease, lung function and Charlson index of co-morbidity were collected.
A comprehensive assessment, including dyspnea, lung function, six-minute walking test, and
St. George’s Respiratory Questionnaire (SGRQ), was completed 3 months after admission,
during a clinically stable disease period.
Results: Three-hundred and forty-two patients (57% of the eligible) participated in the study:
93% males, mean (SD) age 68 (9) years, 42% current smokers, 50% two or more co-morbidities,
54% mild-to-moderate dyspnea, post-bronchodilator FEV1 52 (16)% of predicted (54% mild-to-
moderate COPD in ATS/ERS stages), 6-min walking distance 440 m, total SGRQ score 37 (18),
and 36% not report respiratory disease. The absence of a previous COPD diagnosis, positive
bronchodilator test, female gender, older age, higher DLco and higher BMI were independently
associated with less severe COPD.
Conclusions: We show that the patients admitted after presenting with their first COPD exac-
erbation have a wide range of severity, with a large proportion of patients in the less advanced
COPD stages.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is associated
with a significant and increasing burden worldwide. It has
been estimated that it will become the third most common
cause of death and the fifth leading cause of disability-
adjusted life years by 2020.1,2 Hospitalisations due to
a COPD exacerbation have a significant impact on the
natural history of the disease and represent the most
important direct healthcare costs associated with COPD.1,2
Several studies highlighted the fact that COPD is frequently
underdiagnosed in the community and, as a consequence,
a substantial proportion of patients do not receive appro-
priate treatment or adequate follow-up,3e5 which may
increase the risk of exacerbations and the need for hospi-
talisation. The first hospital admission for a COPD exacer-
bation may provide a window of opportunity for the
diagnosis of COPD, assessment of its severity and the
initiation of appropriate therapy, including modifications to
lifestyle.6 In addition, there is evidence that even after
a first admission for an exacerbation, the prognosis of COPD
patients is poor. Information about the degree of airflow
limitation or other severity markers, as well as other organ
alterations, could all contribute to explain the significant
mortality that has been previously reported concerning
COPD patients after the first hospital admission.7e9
However, most published studies of patients admitted foran exacerbation of COPD include a large proportion of
patients with previous admissions, so those published
conclusions may not be applicable to patients admitted for
the first time.10,11 Therefore, the clinical and functional
characteristics of the patients admitted to hospital for the
first time presenting with COPD exacerbation are not
known.
The PAC-COPD project is a prospective multicentre study
aimed at both investigating the phenotype heterogeneity of
COPD patients at the time of first admission for an exac-
erbation and assessing the relationship between the
described phenotypes and COPD course.12 The present
paper aims to describe the sociodemographic characteris-
tics, lifestyle, clinical-functional characteristics and co-
morbidities of patients admitted for the first time for
a COPD exacerbation, both at the time of admission and
after reaching clinical stability.
Methods
Design
The PAC-COPD project includes a cross-sectional design and
a follow-up of 5 years. The present paper is based on the
cross-sectional phase of the PAC-COPD, which included
a recruitment visit (during the hospital admission) and
a subsequent hospital visit after reaching clinical stability.
First hospitalisation for a COPD exacerbation 1295Subjects
All subjects admitted for the first time, because of a COPD
exacerbation episode, between January 2004 and March
2006 to nine teaching hospitals in Spain, were recruited. Any
hospital stay or time spent in the emergency room for at
least 18 h with a clinical diagnosis of COPD exacerbation, was
considered an admission. A COPD exacerbation was defined
as ‘‘a sustained worsening of the patient’s condition, from
the stable state and beyond normal day-to-day variations,
that is acute in onset and necessitates a change in regular
medication in a patient with underlying COPD’’.13 The
criteria for a first admission definition were established by
means of a questionnaire, the patient’s clinical record and
a search of the hospital records. The exclusion criteria were:
(1) patients under 45 years of age; (2) severe co-morbidity,
i.e. tuberculosis with residual lesion affecting more than 1/3
of parenchyma, pneumectomy or diagnosed pneumoconiosis
(nZ 38), advanced cancer (nZ 74), psychiatric disorder
(nZ 33), severe cardiovascular or neurological disease
(nZ 39), and other (nZ 74); (3) mental incapacity
(nZ 75); (4) frail or elderly patients with any disability that
would hinder participation in the study (nZ 99); (5) not
living in the healthcare area of that particular hospital
(nZ 17); and (6) not understanding the language. The
diagnosis of COPD was confirmed by spirometry when the
patient had reached clinical stability (at least 3 months after
discharge), according to a post-bronchodilator FEV1/FVC
0.7.14 COPD severity was defined according to the criteria
of the European Respiratory Society and the American
Thoracic Society (ERS/ATS).14
The protocol was approved by the Ethics Committees of
all the participating hospitals and written informed consent
was obtained from all subjects.Measurements
Upon first time admission (recruitment), patients were
asked to complete an epidemiological questionnaire, which
included: (1) sociodemographic data: age, gender, marital
status, working activity, level of education and socioeco-
nomic status (questions from the EFRAM study);11 (2) life-
style information: smoking 11 and physical activity; and (3)
previous treatment (any pharmacologic treatment the
patient was taken regularly for chronic diseases: name of
the drug, dosage, and mode of delivery) and diagnosis of
respiratory disease. Additionally, the Charlson index of co-
morbidity15 was obtained by a pulmonologist from archived
medical records. Lung function at admission was also
recorded from medical records. Length of stay, need for
non-invasive mechanical ventilation and intensive care unit
(ICU) admission were obtained from the hospital discharge
report. The causes of the COPD exacerbation were obtained
from the list of discharge diagnosis. Available information
about the non-participants was collected from their
medical records.
When clinically stable, at least 3 months after hospital
discharge, patients performed the following tests. To assess
pulmonary function, the following analyses were performed:
forced spirometry and bronchodilator test, static lung
volumes by whole-body plethysmography, diffusing capacityfor carbon monoxide (DLco) and arterial blood gases analysis
while breathing room air at rest. All procedures were
standardised according to the Manual of Procedures for the
Evaluation of Lung Function from the Spanish Society of
Pneumology and Thoracic Surgery.16,17 The bronchodilator
test involved the administration of 400 mg of salbutamol
through a holding chamber and an increase in FEV1 that was
both greater than 200 ml and 12% above the pre-bronchodi-
lator FEV1 was considered significant, according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) recommendations.18 Six minutes walking distance
(6MWD) was obtained, all participating hospitals following
the same protocol adapted from published recommenda-
tions,19,20 and expressed as absolute and percentage of
predicted values.21 This consisted of two attempts (with at
least a 30-min rest between them) in 30-m corridors.
Encouragement was given every 1 min and the test was
interrupted if symptoms of exhaustion appeared. Patients
also answered an epidemiological questionnaire, including
the dyspnea assessment using the Modified Medical Research
Council (MMRC) scale22 and a health status measurement
(the validated Spanish version of St. George’s Respiratory
Questionnaire (SGRQ)).23 Body mass index (BMI, kg/m2) and
the BODE index were calculated for each patient.24
A quality control protocol was applied in the different
phases of the study. During preparation of the protocol and
before data collection, test protocols were homogenised
according to local and international guidelines, qualified
staff was selected and trained, and questionnaires and
forms were designed allowing to automation of filter vari-
ables and definition of intervals. Throughout the data
collection process, periodic telephone conversations with
data collection managers were held to comment on doubts
and problems, follow-up forms for patient selection and
performance of tests were dispatched weekly to draw up
summary tables and detect delays or errors, results of tests
were dispatched monthly to detect and resolve errors or
protocol deviations, interviews were taped for later eval-
uation at the coordinating site using a standard form, and
annual visit to sites were done to observe the interviews
and test processes and to detect possible errors or protocol
deviations. After data collection, data were double entered
calculating the number and percentage of inconsistent data
entries per test, per site, and per data input clerk, data
were checked searching for improbable data, inconsis-
tencies, and lost data, and distribution of data and of lost
data was analysed by trend over time, by hospital, and by
interviewer.Statistical analysis
The results are expressed as mean  SD or median (IQR,
25th to 75th percentiles), depending on their distribution
for quantitative variables, and as frequencies and
percentages for qualitative variables. Comparison
between the participant and non-participant groups was
performed by means of an unpaired t-test for quantitative
variables with normal distribution, a ManneWhitney
U-rank test for quantitative variables without normal
distribution and a chi-square or Fischer’s exact test for
qualitative variables. All sociodemographic, lifestyle,
Candidates
n=1,102
Excluded
n=413
Non participants
n=183
Participants
n=506
Causes of non-participation:
Refusal (n=160)
Discharge before the
interview (n=23)
Excluded
n=36
Causes of exclusion:
Advanced cancer (n=11)
Severe respiratory disease (n=3)
Severe cardiovascular disease (n=3)
Psychiatric disorder (n=0)
Other severe comorbidities (n=8)
Mental incapacity (n=0)
Frailty (n=4)
Not living in the area (n=7)
Causes of exclusion:
Advanced cancer (n=63)
Severe respiratory disease (n=35)
Severe cardiovascular disease (n=36)
Psychiatric disorder (n=33)
Other severe comorbidities (n=66)
Mental incapacity (n=75)
Frailty (n=95)
Not living in the area (n=10)
Non COPD (FEV1/FVC > 0.7)
n=49
Non participants
n=79
Participants
n=342
Causes of non-participation:
Death (n=12)
Refusal (n=53)
Lost to follow-up (n=14)
TOTAL ELIGIBLE N=604
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Figure 1 Flow chart of candidate patients from the first COPD admission to clinical stability, specifying their eligibility and
willingness to participate, as well as exclusion or non-participation reasons.
1296 E. Balcells et al.medical care-related, clinical and functional variables of
patients were compared between severity stages of COPD
using ANOVA or Kruskall Wallis (for quantitative variables)
and chi-square or Fisher’s exact test (for qualitative vari-
ables). To identify the variables independently associated
with being in a mild-to-moderate COPD stage, with severe
and very severe stages as the reference groups, we built
a multivariate logistic regression model. First, all variables
that were associated with COPD severity in the bivariate
analysis were included. Finally, a model with only inde-
pendently statistically associated variables was obtained.
Results were considered statistically significant at
p < 0.05. The analyses were performed with SPSS version
11.5 (2002, SPSS Inc., Chicago, IL, USA).Results
A total of 604 eligible subjects were identified and 342
(56.6% of them) accepted to participate. (Fig. 1). The most
frequent cause of the COPD exacerbation was infection,
usually tracheobronchial infection in 172 patients (50.3%),
or pneumonia in 79 patients (23.1%); in the remaining 91
(26.6%) the cause was not identified. Table 1 shows that the
parameters obtained during hospitalisation, including age,
gender, marital status, Charlson index score, length of
hospital stay and the mean of the predicted FEV1 (%), were
similar between participants and non-participants. Non-
participants were more likely to have never been smokers
and to have congestive heart failure. Table 1 shows thesociodemographic characteristics, lifestyle and co-morbid-
ities of the study sample at admission. Mean (SD) age was
67.5 (8.5) years and 318 patients (93%) were males. Up to
42.4% of the patients were current smokers. At least two
co-morbidities were found in 172 patients (50.3%). Two
hundred and nineteen patients (64%) reported a previous
diagnosis of respiratory illness and 193 patients (56.4%)
were receiving some pharmacological treatment for respi-
ratory disease before exacerbation. The comparison
between males (nZ 318) and females (nZ 24) (not pre-
sented in tables) showed that the females were younger
(58.7 (7.7) vs. 68.1 (8.2) years, p < 0.001), with a higher
proportion of those who reported being current smokers
(79.2% vs. 39.6%, p < 0.001) being unmarried (41.7% vs.
18.2%, pZ 0.013) and of a high socioeconomic status
(52.4% vs. 15.9%, p < 0.001). No statistically significant
differences were found in the percentage of patients with
more than one co-morbidity between females and males
(37.5% vs. 51.3%, respectively, pZ 0.194).
The characteristics of the study sample at stability are
summarised in Table 2. A wide range of severity was found,
although the majority of patients had moderate-to-severe
COPD. The mean (SD) post-bronchodilator FEV1 was 52.4%
(16.2) of predicted. Most patients showed air trapping
(measured by residual volume/total lung capacity, RV/TLC)
and a mild decrease of DLco. Twenty-one patients (6.3%) had
respiratory failure (PaO2 <60 mmHg) and of those, 15 (4.5%)
were also hypercapnic (PaCO2 >45 mmHg). The mean (SD)
BMI was 28.2 (4.7) (kg/m2). Quality of life was moderately
affected, mostly in the symptoms and activity score. There
Table 1 Sociodemographic characteristics, lifestyle and co-morbidities of COPD patients at the time of their first admission
presenting with an exacerbation. Comparison between participants and non-participants.
Characteristics Participants (nZ 342)a Non-participants (nZ 262)a p
Sociodemographic factors
Males, n (%) 318 (93.0) 233 (89.3) 0.108
Age (years), mean (SD) 67.5 (8.5) 68.8 (9.2) 0.065
Married, n (%) 274 (80.1) 195 (75.0) 0.134
Less than primary education, n (%) 142 (41.5) e e
Low socioeconomic status (IV-V), n (%)b 259 (81.7) e e
Current workers, n (%) 61 (17.8) e e
Lifestyle
Smoking, n (%)
Current smoker 145 (42.4) 119 (46.1) 0.028
Ex-smoker 195 (57.0) 131 (50.8)
Never smoker 2 (0.6) 8 (3.1)
Pack-years, mean (SD) 65.9 (41.2) 63.3 (55.5) 0.651
Usual physical activity (h/week), median(P25eP75) 28.5 (13.9e45.8) e e
Co-morbiditiesc
Myocardial infarction, n (%) 34 (9.9) 20 (7.6) 0.325
Congestive heart failure, n (%) 17 (5.0) 24 (9.2) 0.042
Peripheral vascular disease, n (%) 32 (9.4) 28 (10.7) 0.588
Cerebrovascular disease, n (%) 12 (3.5) 18 (6.9) 0.059
Connective tissue disease, n (%) 6 (1.8) 4 (1.5) 1.000
Ulcer disease, n (%) 37 (10.8) 33 (12.6) 0.499
Mild liver disease, n (%) 14 (4.1) 13 (5.0) 0.609
Diabetes, n (%) 61 (17.8) 52 (19.8) 0.530
Hemiplegia, n (%) 2 (0.6) 1 (0.4) 1.000
Moderate or severe renal disease, n (%) 20 (5.8) 11 (4.2) 0.363
Diabetes with end organ damage, n (%) 6 (1.8) 7 (2.7) 0.441
Any malignancy, n (%) 33 (9.6) 18 (6.9) 0.223
Moderate or severe liver disease, n (%) 2 (0.6) 4 (1.5) 0.411
Charlson index, mean (SD) 2.0 (1.3) 2.0 (1.3) 0.602
Number Charlson co-morbidities, n (%)
1 170 (49.7) 123 (46.9) 0.501
2 172 (50.3) 139 (53.1)
Other
Length of hospital stay (days), median (P25eP75) 7 (4e10) 6 (4e10) 0.972
ICU admission, n (%) 16 (4.7) e e
Non-invasive mechanical ventilation, n (%) 15 (4.4) e e
FEV1 (% pred.) during admission, mean (SD) 47.0 (16.5) 47.8 (17.5) 0.725
Previous diagnosis of respiratory illness (self-reported), n (%) 219 (65.0) 48 (61.5) 0.703
Any respiratory drug treatment, n (%) 193 (56.4) 145 (55.3) 0.789
a Some variables had missing values: two in marital status, four in smoking status, 183 in pack-years of smoking, 164 in % FEV1 and 184
in previous diagnosis of respiratory illness (non-participants), 25 in socioeconomic status, one in pack-years of smoking, one in physical
activity and 220 in % FEV1 (participants).
b According to the International Standard Classification of Occupations (ISCO).
c Other co-morbidities included in the Charlson index (dementia, metastatic malignancies or AIDS) are not shown because of the lack
of patients with such diseases.
First hospitalisation for a COPD exacerbation 1297were no significant differences between genders in air
trapping and DLco, dyspnea score, 6MWD and BMI. However,
females reported a previous diagnosis of respiratory illness in
a lower proportion than males, showed less severe airflow
obstruction and scored better in the SGRQ activity index.
The characteristics of patients, according to COPD
severity, are reported in Table 3. The proportion of males
was lower in mild COPD, but there were no differences inthe remaining sociodemographic characteristics, lifestyle
and Charlson co-morbidities. The proportion of patients
who were using respiratory drug treatment and reported
a previous diagnosis of respiratory disease was higher in
more severe COPD individuals. There were relevant
differences between the stages of severity in the majority
of the clinical and functional variables. Among the patients
with a first admission due to a COPD exacerbation, the
Table 2 Clinical and functional characteristics of the 342 COPD patients under stable conditions following their first admission
for a COPD exacerbation.
Characteristicsa Total (nZ 342) Males (nZ 318) Females (nZ 24) p
Previous diagnosis of respiratory illness
(self-reported), n (%)
219 (64.0) 208 (65.4) 11 (45.8) 0.046
Any respiratory drug treatment, n (%) 193 (56.4) 182 (57.2) 11 (45.8) 0.277
MMRC dyspnea scale, mean (SD) 2.60 (1.35) 2.64 (1.34) 2.08 (1.41) 0.055
Grade 0, n (%) 27 (8.0) 24 (7.6) 3 (13.0)
Grade 1, n (%) 15 (4.4) 12 (3.8) 3 (13.0)
Grade 2, n (%) 142 (42.0) 130 (41.3) 12 (52.2)
Grade 3, n (%) 85 (25.1) 83 (26.3) 2 (8.7)
Grade 4, n (%) 17 (5.0) 17 (5.4) e
Grade 5, n (%) 52 (15.4) 49 (15.6) 3 (13.0)
FVC (l), mean (SD) 2.75 (0.73) 2.78 (0.73) 2.39 (0.64) 0.013
FVC (% pred), mean (SD) 68.7 (16.2) 67.9 (15.6) 78.7 (20.3) 0.002
FEV1 (l), mean (SD) 1.44 (0.52) 1.46 (0.52) 1.30 (0.46) 0.162
FEV1 (% pred), mean (SD) 48.7 (15.6) 48.1 (15.2) 56.2 (18.6) 0.015
PostBD FEV1 (% pred), mean (SD) 52.4 (16.2) 51.7 (15.9) 61.8 (17.9) 0.003
PostBD FEV1/FVC (%), mean (SD) 53.4 (11.9) 53.3 (12.1) 54.9 (10.5) 0.524
COPD severity, n (%)b
I: Mild (FEV1 80%), n (%) 19 (5.6) 15 (4.7) 4 (16.7) 0.015
II: Moderate (FEV1 50%, <80%), n (%) 164 (48.0) 149 (46.9) 15 (62.5)
III: Severe (FEV1 30%, <50%), n (%) 132 (38.6) 128 (40.3) 4 (16.7)
IV: Very severe (FEV1 <30%), n (%) 27 (7.9) 26 (8.2) 1 (4.2)
RV/TLC (%), mean (SD) 55.5 (10.0) 55.5 (10.0) 56.0 (11.2) 0.814
DLco (% pred), mean (SD) 65.2 (20.7) 65.4 (20.8) 63.1 (19.1) 0.627
Bronchodilator test, n (%)c 69 (21.0) 63 (20.7) 6 (25.0) 0.621
PaO2 (mmHg), mean (SD) 74.3 (10.6) 74.5 (10.8) 72.1 (8.4) 0.300
PaCO2 (mmHg), mean (SD) 41.8 (5.3) 41.8 (5.5) 42.1 (3.5) 0.618
Body mass index (kg/m2), mean (SD) 28.2 (4.7) 28.3 (4.5) 26.5 (6.5) 0.204
6MWD (m), median (P25eP75)
d 440.0 (390.0e509.2) 441.4 (390.0e509.6) 428.0 (378.4e510.2) 0.526
6MWD (% pred), median (P25eP75) 90.0 (79.8e103.0) 90.7 (79.8e103.2) 86.1 (75.8e96.1) 0.221
SGRQ score (0, no health impairment to 100,
maximum impairment), m(SD)
Symptoms, mean (SD) 48.5 (17.6) 48.4 (17.7) 49.8 (17.3) 0.718
Activity, mean (SD) 47.3 (24.5) 48.3 (24.0) 33.7 (27.8) 0.006
Impacts, mean (SD) 26.5 (18.5) 26.7 (18.6) 22.8 (18.1) 0.331
Total, mean (SD) 36.5 (17.8) 36.9 (17.7) 30.7 (18.3) 0.105
BODE index score (from 0 to 10), median (P25eP75) 2 (1e3) 2 (1e3) 1 (0e2) 0.011
a Some variables had missing values: four in dyspnea, 27 in RV/TLC, 46 in DLco, 11 in PaO2, 10 in PaCO2, 33 in 6MWD, four in SGRQ
score, 14 in bronchodilator test and 34 in BODE index.
b According to the criteria of the ERS/ATS (14).
c Change in FEV1 200 ml and 12%.
d 6-minute walking distance; the best of two 6-minute-walk tests separated by 30 min.
1298 E. Balcells et al.following variables showed significant and independent
association with a mild-to-moderate stage of COPD: female
gender, a significant bronchodilator test, no report of
previous diagnosis of respiratory illness, higher DLco (%
predicted), higher BMI and older age (Table 4).
Discussion
This is the first study that characterises a large and repre-
sentative sample of the patients admitted after presentingwith an exacerbation of COPD for the first time. In general,
the patients in our sample population were relatively old,
had more than one chronic co-morbid condition, a high
proportion were current smokers and more than one third
did not report a previous diagnosis of respiratory illness. At
a period of COPD stability, these patients demonstrated
a wide range of disease severity, with a mean post-bron-
chodilator FEV1 value of about 50% of that predicted, and
they reported a moderate degree of dyspnea and moderate
impairment in quality of life. Multivariate analysis
Table 3 General characteristics of the 342 COPD patients admitted for the first time following an exacerbation, according to disease severity.
Characteristics Stage I (nZ 19) Stage II (nZ 164) Stage III (nZ 132) Stage IV (nZ 27) p
Age (years), mean (SD) 67.4 (8.5) 67.6 (8.9) 68.1 (8.0) 64.0 (8.6) 0.154
Males, n (%) 15 (78.9) 149 (90.9) 128 (97.0) 26 (96.3) 0.015
Married, n (%) 19 (100.0) 131 (79.9) 105 (79.5) 19 (70.4) 0.060
Less than primary education, n (%) 10 (52.6) 64 (39.0) 56 (42.4) 12 (44.4) 0.676
Low socioeconomic status, n (%) 16 (84.2) 123 (83.1) 100 (80.6) 20 (76.9) 0.842
Current workers, n (%) 2 (10.5) 32 (19.5) 22 (16.7) 5 (18.5) 0.822
Smoking, n (%)
Current smoker 7 (36.8) 70 (42.7) 54 (40.9) 14 (51.9) 0.354
Ex-smoker 11 (57.9) 93 (56.7) 78 (59.1) 13 (48.1)
Never smoker 1 (5.3) 1 (0.6) e e
Usual physical activity (hours/week), median (P25eP75) 34.0 (11.3e58.0) 32.0 (16.7e49.3) 22.6 (11.1e42.4) 23.5 (14.0e46.7) 0.134
Previous diagnosis of respiratory illness (self-reported), n (%) 6 (31.6) 98 (59.8) 96 (72.7) 19 (70.4) 0.009
Any respiratory drug treatment, n (%) 5 (26.3) 82 (50.0) 88 (66.7) 18 (66.7) 0.001
Charlson index, mean (SD) 2.0 (1.7) 2.0 (1.3) 2.0 (1.4) 1.9 (1.3) 0.989
MMRC dyspnea score, mean (SD) 1.73 (1.36) 2.29 (1.25) 2.88 (1.29) 3.74 (1.19) <0.001
RV/TLC (%), mean (SD) 44.5 (9.4) 51.5 (8.5) 60.3 (8.0) 67.7 (7.7) <0.001
DLco (%pred), mean (SD) 90.7 (18.4) 70.2 (17.9) 59.4 (18.4) 41.4 (21.1) <0.001
PaO2 (mmHg), mean (SD) 82.1 (10.9) 76.5 (10.8) 71.9 (9.5) 67.3 (7.6) <0.001
PaCO2 (mmHg), mean (SD) 39.8 (4.3) 40.4 (4.8) 42.8 (5.4) 46.2 (5.2) <0.001
Bronchodilator test, n (%) 9 (50.0) 36 (22.9) 23 (18.0) 1 (4.0) 0.003
6MWD (m), median (P25eP75) 460.0 (389.9e540.0) 442.6 (390.0e510.0) 441.0 (396.5e504.3) 417.5 (337.0e466.8) 0.119
6MWD (% pred), median (P25eP75) 94.4 (86.4e107.1) 92.5 (82.0e103.3) 88.0 (79.7e103.1) 77.0 (59.4e91.1) <0.001
Body mass index (kg/m2), mean (SD) 29.1 (5.2) 29.2 (4.4) 27.7 (4.5) 23.9 (4.3) <0.001
SGRQ score, mean (SD)
Symptoms, mean (SD) 47.2 (13.8) 45.4 (16.5) 50.5 (18.4) 58.3 (18.7) 0.002
Activity, mean (SD) 27.5 (21.5) 39.8 (21.3) 54.4 (23.5) 71.2 (21.4) <0.001
Impacts, mean (SD) 13.4 (10.3) 22.0 (16.4) 30.5 (18.2) 43.2 (21.2) <0.001
Total, mean (SD) 23.5 (11.5) 31.4 (15.1) 41.1 (17.4) 54.2 (18.8) <0.001
BODE index, median (P25eP75) 0 (0e1) 1 (1e2) 3 (2e5) 5 (4e7) <0.001
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Table 4 Variables that were independently related to
being in a mild-to-moderate stage of COPD in a sample
population of 342 patients admitted for the first time for
COPD exacerbation.
Variables OR (95% CI) p
Age (years) 1.07 (1.02e1.13) 0.002
Gender: females 16.80 (2.89e97.46) 0.002
No previous diagnosis of
respiratory illness
2.29 (1.03e5.08) 0.042
Degree of dyspnea (score from
0 to 5)
0.68 (0.50e0.91) 0.011
Significant bronchodilator test
Change in FEV1 200 ml and
12%
3.37 (1.35e8.40) 0.009
DLco (%pred) 1.03 (1.01e1.06) 0.001
RV/TLC (%) 0.84 (0.79e0.88) <0.001
PaCO2 (mmHg) 0.89 (0.83e0.96) 0.003
BMI (kg/m2) 1.11 (1.01e1.21) 0.028
OR, odds ratio; CI, confidence interval.
1300 E. Balcells et al.identified that female gender, older age, a significant
bronchodilator response, no report of previous diagnosis of
respiratory illness, a higher percentage of predicted DLco
and a higher value of BMI were significantly and indepen-
dently associated with being in the early stages of the
disease at the first hospitalisation.
Prognosis is poor for patients after the first hospital
admission for a COPD exacerbation. For example, a recent
study of compiled data from both hospital and mortality
registers reported that about 20% of patients have a 1-year
mortality rate following the first COPD-associated hospital
admission.9 Similar mortality rates were reported for 49
patients from a cohort of 205 patients that had been
recruited for COPD exacerbation-associated first time hos-
pitalisation.10 Likewise, a prospective study involving 304
COPD patients followed up for 5 years demonstrated that
patients with only one COPD-related hospital admission had
a poorer survival rate than those patients who were not
hospitalised following an emergency room visit.25 Surpris-
ingly, only two previous studies provide any information on
the characteristics of the few patients, admitted for the
first time for a COPD exacerbation, and those studies were
focused on the prevalence of modifiable risk factors
of exacerbation26 and the implementation of the British
Thoracic Society guidelines.27
In general, the studies investigating patients admitted
for COPD exacerbation are predominantly focused on
patients with severe and very severe airflow obstruc-
tions.10,26,28 By contrast, more than 50% of our sample
population of first-time hospitalised COPD patients had
mild-to-moderate disease. It is unlikely that the first
hospital admission of COPD patients with less advanced
disease was precipitated by sociodemographic factors or
co-morbidities, because only older age and female gender
were significantly associated with mild-to-moderate stage
and there were no differences between patients with
different degrees of airflow limitation within the remaining
sociodemographic factor subgroups (socioeconomic status,
education level or marital status) or co-morbidities. Inter-
estingly, we have observed a strong association betweenhaving mild-to-moderate disease and the absence of
a previous diagnosis of respiratory disease, which was
similarly reported in a population-based study.29 It is more
likely that the absence of COPD diagnosis, and therefore,
a lack of appropriate treatment, may have facilitated the
admission. In fact, it has been observed that the lack of
awareness of respiratory disease in mild COPD (68%) is
similar to the proportion of COPD under-diagnosis reported
in a Spanish population-based study.3 It is noteworthy that
the percentage of under-diagnosis is still high (up to 30%) in
the severe and very severe COPD patients. These observa-
tions reinforce the importance of accurate COPD diagnosis
and the implementation of appropriate therapeutic
measures at the first hospital admission so that the disease
can be properly managed at the earlier stages, which is
more likely to halt or reduce the progression of the disease.
It is of particular interest that about 40% of patients were
current smokers.
An important observation from our study is that
a considerable proportion of patients had a significant
bronchodilator response, which is associated with mild-to-
moderate airflow obstruction. In fact, bronchodilator
reversibility has already been detected in COPD patients
with a wide spectrum of disease severity.30,31 In the Lung
Health Study, large bronchodilator responses were
uncommon in COPD patients with FEV1 values above 55% of
the predicted.30 However, more recently, another large
study has reported a substantial percentage of bronchodi-
lator reversibility in COPD patients that decreased
progressively with increasing disease severity,31 which is
consistent with our results. We speculate that the presence
of a significant bronchodilator response could be a factor
that contributes to first time hospitalisation in patients
with less advanced disease and may increase the proba-
bility of being admitted with less severe disease.
Our results describe the distribution of relevant prog-
nostic factors in COPD, such as airflow limitation, dyspnea,
exercise capacity, nutritional depletion and health status.32
We have already discussed that the airflow limitation was
only mild-to-moderate in more than 50% of the studied
patients. Although the vast majority of patients had a dysp-
nea of grade two to three, a large percentage of the patients
reported very severe dyspnea at the stability assessment. In
contrast, exercise capacity (as measured by the 6MWD) was
only significantly affected in the very severe stage of disease.
In fact, data from the original BODE cohort suggests that
COPD patients from Spain walk more than the group from the
United States.33 Likewise, we found that the prevalence of
a low body weight (defined by a BMI<20 kg/m2) in the studied
patients was only 2.9%, a substantially lower percentage
than reported in other studies,34 but consistent with
previous studies that included patients with moderate-to-
severe COPD from a Mediterranean population.35 Finally,
our patients exhibited higher scores in all the domains of
the SGRQ (worse health-related quality of life), compared
with the reference values for COPD provided by the
IBERPOC study of the general population of 40e69-year
old patients.36
The prevalence of COPD in females is increasing world-
wide, which is likely the result of changing trends in ciga-
rette consumption, with increased smoking among females.
Despite this trend, most studies that recruited COPD
First hospitalisation for a COPD exacerbation 1301patients presenting with exacerbation have tended to focus
on males. Only recently have some studies found gender
differences in quality of life, symptoms, exercise capacity
and health care use, while other studies have shown
a gender bias in the diagnosis of COPD.37,38 Our cohort
included only 24 females with COPD (7% of the sample),
which is a percentage slightly higher than the 4% described
in a general population Spanish study in 1997,3 although
still much lower than the observed in other European
countries.18 Such a small number of women makes it diffi-
cult to draw conclusions about gender differences in
patients admitted for the first time for COPD exacerbation.
It is worth mentioning that there were differences in soci-
odemographic profile and lower degree of airflow obstruc-
tion in females, with a male:female ratio of 4:1 in the mild
stage. It is likely that this difference observed in COPD
severity could be explained, in part, by the younger ages of
the included women.
Our study does have some limitations worth noting.
First, non-participation could have lead to selection bias,
since the studied sample population only included 56.6% of
the total number of patients, presenting with COPD exac-
erbation, admitted for the first time. Most likely the non-
participation was, in part, the result of the large number of
tests performed during the study. The lack of difference
between the non-participants and participants suggests
that any selection bias, if present, is small. Second, co-
morbidities may have been underestimated, since COPD
patients with cardiovascular and cerebrovascular diseases
and cancer were excluded, as typically occurs in studies
with similar characteristics. However, a strength of the
design, in contrast to other studies, is that the patients
were recruited not only from the pulmonology ward, but
also from all other clinical wards, which provides more
reliable information regarding co-morbidities. Third, our
study could possibly be criticized for the large range of
inclusion criteria, without excluding non-smokers or
patients with significant bronchodilator response. We chose
these inclusion and exclusion criteria so that the PAC-COPD
project would be aimed at investigating the phenotype
heterogeneity of COPD at the time of first admission for an
exacerbation. Thus, the use of more restrictive criteria
could possibly have resulted in some phenotype or clinical
expression of COPD being omitted. It is well known that
a differential diagnosis from asthma can be difficult in some
subjects and that the two diseases can overlap. In our
study, the differential diagnosis from asthma was based on
medical history; all patients recruited were carefully clin-
ically evaluated by a pulmonologist participating in the
study, with the clear objective to include patients without
other features of asthma.
Finally, our findings might not be applicable to the first-
time hospitalised COPD patients with an exacerbation from
other countries that have different social and sanitary
organisations. However, since there is currently a lack of
relevant COPD patient characteristics information at their
first admission, the results presented in this study provide
a good reference point for similar studies in other
countries.
In conclusion, we show that the patients admitted after
presenting with their first COPD exacerbation have a wide
range of severity,witha largeproportionofpatients in the lessadvanced COPD stages. We found that the patients admitted
for the first time are likely to have mild-to-moderate COPD if
they are females, have a significant bronchodilator response
and do not report a previous diagnosis of respiratory illness. A
detailed and systematic assessment of COPD patients
admitted after presenting with their first exacerbation would
allow for an earlier and better-planned therapeutic treat-
ment strategy that has the potential to be tailored to each
COPD patient.
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